Actively Recruiting
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Led by University of Chicago · Updated on 2025-10-01
155
Participants Needed
2
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
CONDITIONS
Official Title
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prostate cancer with more than 3 years of LHRH agonist therapy
- Age 70 years or older
- ECOG performance status of 2 or less
- Baseline testosterone level less than 20 ng/ml
- No prior chemotherapy or Lu-PSMA unless survival predictions are favorable
- Ability to understand and sign informed consent
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The University of Illinois at Chicago (UIC)
Chicago, Illinois, United States, 60607
Actively Recruiting
2
UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
Not Yet Recruiting
Research Team
C
Clinical Trials Intake
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here